| High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial BH Grønberg, KT Killingberg, Ø Fløtten, OT Brustugun, K Hornslien, ... The Lancet Oncology 22 (3), 321-331, 2021 | 106 | 2021 |
| First clinical experiences with a high field 1.5 T MR linac AS Bertelsen, T Schytte, PK Møller, F Mahmood, HL Riis, KL Gottlieb, ... Acta Oncologica 58 (10), 1352-1357, 2019 | 106 | 2019 |
| Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local … SS Jeppesen, T Schytte, HR Jensen, C Brink, O Hansen Acta Oncologica 52 (7), 1552-1558, 2013 | 85 | 2013 |
| Locoregional control of non-small cell lung cancer in relation to automated early assessment of tumor regression on cone beam computed tomography C Brink, U Bernchou, A Bertelsen, O Hansen, T Schytte, SM Bentzen International Journal of Radiation Oncology* Biology* Physics 89 (4), 916-923, 2014 | 84 | 2014 |
| Radiation dose response of normal lung assessed by Cone Beam CT–a potential tool for biologically adaptive radiation therapy A Bertelsen, T Schytte, SM Bentzen, O Hansen, M Nielsen, C Brink Radiotherapy and Oncology 100 (3), 351-355, 2011 | 67 | 2011 |
| Delineation of whole heart and substructures in thoracic radiation therapy: National guidelines and contouring atlas by the Danish Multidisciplinary Cancer Groups MLH Milo, BV Offersen, T Bechmann, ACP Diederichsen, CR Hansen, ... Radiotherapy and Oncology 150, 121-127, 2020 | 65 | 2020 |
| Time evolution of regional CT density changes in normal lung after IMRT for NSCLC U Bernchou, T Schytte, A Bertelsen, SM Bentzen, O Hansen, C Brink Radiotherapy and Oncology 109 (1), 89-94, 2013 | 60 | 2013 |
| Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment RL Christiansen, L Dysager, CR Hansen, HR Jensen, T Schytte, ... Radiotherapy and Oncology 167, 165-171, 2022 | 56 | 2022 |
| Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study B Bjørnhart, KH Hansen, TL Jørgensen, J Herrstedt, T Schytte Acta Oncologica 58 (7), 953-961, 2019 | 50 | 2019 |
| ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology S Corradini, F Alongi, N Andratschke, D Azria, O Bohoudi, L Boldrini, ... Radiotherapy and Oncology 159, 146-154, 2021 | 45 | 2021 |
| Prediction of lung density changes after radiotherapy by cone beam computed tomography response markers and pre-treatment factors for non-small cell lung cancer patients U Bernchou, O Hansen, T Schytte, A Bertelsen, A Hope, D Moseley, ... Radiotherapy and Oncology 117 (1), 17-22, 2015 | 42 | 2015 |
| Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer T Schytte, O Hansen, T Stolberg-Rohr, C Brink Acta Oncologica 49 (7), 1058-1060, 2010 | 36 | 2010 |
| Pemetrexed safety and pharmacokinetics in patients with third-space fluid NJ Dickgreber, JB Sorensen, LG Paz-Ares, TK Schytte, JE Latz, ... Clinical Cancer Research 16 (10), 2872-2880, 2010 | 33 | 2010 |
| Impact of comprehensive geriatric assessment on quality of life, overall survival, and unplanned admission in patients with non-small cell lung cancer treated with stereotactic … SS Jeppesen, LE Matzen, C Brink, R Bliucukiene, S Kasch, T Schytte, ... Journal of geriatric oncology 9 (6), 575-582, 2018 | 32 | 2018 |
| Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): design and early dosimetric results of a randomized, multi-centre phase-III study DS Møller, TB Nielsen, C Brink, L Hoffmann, CM Lutz, MD Lund, ... Radiotherapy and Oncology 124 (2), 311-317, 2017 | 32 | 2017 |
| Pattern of loco-regional failure after definitive radiotherapy for non-small cell lung cancer T Schytte, TB Nielsen, C Brink, O Hansen Acta Oncologica 53 (3), 336-341, 2014 | 31 | 2014 |
| Acute esophagitis for patients with local–regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy Y Pan, C Brink, M Knap, AA Khalil, CH Nyhus, T McCulloch, B Holm, Y Wu, ... Radiotherapy and Oncology 118 (3), 465-470, 2016 | 29 | 2016 |
| Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—Real world efficacy MT Mouritzen, A Carus, M Ladekarl, P Meldgaard, AWM Nielsen, ... Cancers 13 (19), 4846, 2021 | 28 | 2021 |
| A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60 Gy and 66 Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced … O Hansen, MM Knap, A Khalil, CH Nyhus, T McCulloch, B Holm, C Brink, ... Radiotherapy and Oncology 123 (2), 276-281, 2017 | 27 | 2017 |
| Inhomogeneous dose escalation increases expected local control for NSCLC patients with lymph node involvement without increased mean lung dose TB Nielsen, O Hansen, T Schytte, C Brink Acta Oncologica 53 (1), 119-125, 2014 | 24 | 2014 |
